SNGX Stock Overview
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Soligenix, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.61 |
52 Week High | US$4.20 |
52 Week Low | US$0.38 |
Beta | 1.83 |
1 Month Change | -11.47% |
3 Month Change | 5.35% |
1 Year Change | -71.76% |
3 Year Change | -97.64% |
5 Year Change | -95.85% |
Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma
Oct 05U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer
Sep 12Soligenix announces $2.6M FDA grant to further study blood cancer candidate
Sep 06Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Sep 06Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M
Aug 12Soligenix, SERB Pharma team up to develop therapy for ricin poisoning
Jul 25Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Apr 22Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?
Jan 03Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now
Sep 17Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?
Aug 30Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?
May 08What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Mar 16Soligenix inks supply and distribution deal for SGX301 companion light device in cancer
Jan 07Soligenix receives $1.5M grant advancing COVID-19 vaccine development
Dec 28Soligenix's SGX942 flunks oral mucositis study in cancer patients, shares plummet 44%
Dec 22Soligenix announces $20M strategic convertible debt financing agreement
Dec 16Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters
Nov 20Shareholder Returns
SNGX | US Biotechs | US Market | |
---|---|---|---|
7D | -17.2% | -2.1% | 0.5% |
1Y | -71.8% | 9.7% | 29.0% |
Return vs Industry: SNGX underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: SNGX underperformed the US Market which returned 28.4% over the past year.
Price Volatility
SNGX volatility | |
---|---|
SNGX Average Weekly Movement | 13.0% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SNGX's share price has been volatile over the past 3 months.
Volatility Over Time: SNGX's weekly volatility has decreased from 25% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 14 | Christopher Schaber | https://www.soligenix.com |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.
Soligenix, Inc. Fundamentals Summary
SNGX fundamental statistics | |
---|---|
Market cap | US$6.42m |
Earnings (TTM) | -US$6.14m |
Revenue (TTM) | US$839.36k |
7.6x
P/S Ratio-1.0x
P/E RatioIs SNGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SNGX income statement (TTM) | |
---|---|
Revenue | US$839.36k |
Cost of Revenue | US$742.05k |
Gross Profit | US$97.31k |
Other Expenses | US$6.24m |
Earnings | -US$6.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.58 |
Gross Margin | 11.59% |
Net Profit Margin | -731.60% |
Debt/Equity Ratio | 129.3% |
How did SNGX perform over the long term?
See historical performance and comparison